Flexible Clinical Operations and Site Management Across a Diversified Biotech Portfolio: An Application of Quality by Design and Risk-Based Oversight

Abstract

• Background: Emerging biotechnology companies frequently encounter operational challenges as their clinical development portfolios expand across multiple indications and study phases. Ensuring consistent quality, regulatory compliance, and operational efficiency in this context requires scalable and flexible clinical operations models aligned with evolving regulatory expectations. Key sources include the International Council for Harmonization (ICH) E6 Good Clinical Practice guidelines, FDA guidance, and European Medicines Agency (EMA) scientific guidelines.
• Methods: This paper describes a real‑world case of a sponsor‑agnostic clinical development program supported by a midsize contract research organization (CRO) through an evolving partnership model. The engagement began with targeted clinical monitoring support and expanded to comprehensive clinical operations and site management services across multiple studies. The approach was grounded in quality by design (QbD) principles and risk-based methodologies, aligned with ICH E6(R2) and the finalized ICH E6(R3) guidelines. Furthermore, the framework integrated contemporary FDA guidance on risk-based monitoring and EMA scientific guidelines on risk-based quality management and computerized systems in clinical trials.
• Results: Application of a QbD‑driven, risk‑based operational framework enabled consistent study oversight, improved site performance, and scalable execution across heterogeneous studies and indications. This approach maintained data integrity, ensured participant protection, and demonstrated regulatory compliance across global jurisdictions, including the United States and the European Union.
• Conclusion: A flexible CRO partnership model, informed by QbD and aligned with the latest ICH, FDA, and EMA expectations, can effectively support growing clinical portfolios. This model maintains data integrity, participant protection, and regulatory compliance.

Introduction

The clinical development landscape for emerging biotechnology companies has become increasingly complex. Many organizations advance multiple investigational products concurrently, often across diverse therapeutic indications and development stages.

Although scientific innovation fuels such expansion, operational infrastructure frequently lags behind portfolio growth, placing pressure on internal clinical teams. This challenge is compounded by the dynamic regulatory environment, which continually refines expectations for clinical trial conduct.

Regulatory authorities, including the International Council for Harmonization (ICH), the FDA, and the European Medicines Agency (EMA), have emphasized the importance of risk‑based approaches, quality by design (QbD), and proactive trial oversight to ensure participant safety and data reliability.^1,2

The ICH E6 Good Clinical Practice (GCP) guideline captures the evolution of these expectations, moving from its R2 addendum to the recently finalized E6(R3) version.³ ICH E6(R3) represents a major paradigm shift, integrating concepts such as proportionate oversight, enhanced data integrity, and flexibility for innovation directly into the clinical trial framework, moving beyond the foundational principles of E6(R2).⁴

In the European Union, the EMA has further clarified these expectations through specific scientific guidelines, such as the reflection paper on risk-based quality management in clinical trials and the guideline on computerized systems and electronic data in clinical trials.^5,6 These documents underscore that quality management should be a systematic, prioritized process integrated throughout the trial lifecycle.

In this context, contract research organizations (CROs) play a crucial role in operationalizing these expectations. This paper describes a CRO‑sponsor partnership model designed to support a rapidly expanding, multiple‑indication clinical program.

The case highlights how QbD principles and practices aligned with ICH, FDA, and EMA expectations were embedded into clinical monitoring, site management, and portfolio‑level oversight.

Program Context and Operational Challenges in the Sponsor Environment

The sponsor was an innovation‑driven biotechnology company advancing multiple clinical programs across distinct therapeutic areas. Studies ranged in phase and complexity and were conducted across a mix of academic and community investigative sites.

The key characteristics of the clinical portfolio included:

• Multiple concurrent clinical trials: Managing several trials simultaneously, each with unique requirements and timelines.
• Heterogeneous study designs and endpoints: Diverse protocols demanding adaptable operational strategies.
• Diverse patient populations: Requiring continuously refined approaches to patient recruitment, retention, and safety monitoring.
• Limited internal resources for expanding operational needs: A common constraint for emerging biopharma organizations, this limitation necessitates external support from a CRO that can focus resources on the highest-value activities, reduce waste and rework, and detect problems before they become costly.

Consistent with challenges commonly reported by emerging biopharma organizations, the sponsor faced several crucial issues. These included increasing demand for clinical monitoring and site oversight, which made it difficult to maintain consistency across studies without excessive internal growth. Such growth was not financially viable for the sponsor.

The sponsor also needed to comply with evolving regulatory expectations, including ICH E6(R2) and the anticipated changes in ICH E6(R3), as well as FDA oversight guidance.

The sponsor also wanted to operationalize QbD principles without incurring excessive procedural burden and to seek efficiency without compromising quality or compliance.

CRO Engagement Model and Governance: Phased Engagement Strategy

The CRO engagement was intentionally phased to align with program maturity and operational risk, reflecting a strategic approach to resource allocation and risk management consistent with ICH E6(R3)’s emphasis on proportionate oversight. The process comprised three phases:

• Phase 1: Targeted clinical monitoring support: Initial engagement focused on providing specialized monitoring resources to address immediate needs and establish foundational quality processes.
• Phase 2: Expansion into clinical trial management and site lifecycle oversight: As the partnership matured, the CRO’s role expanded to encompass broader clinical trial management, including comprehensive site selection, initiation, interim monitoring, and close-out activities.
• Phase 3: Portfolio‑level consistency and knowledge transfer across studies: The final phase involved embedding the CRO’s expertise to ensure consistency across the entire portfolio, facilitating knowledge transfer, and establishing robust quality management systems that could be sustained internally.

This phased approach supported scalability while minimizing disruption to ongoing trials, allowing for adaptive integration of CRO services. The partnership incorporated defined communication pathways between sponsor and CRO leadership, regular operational review meetings, and escalation mechanisms aligned with risk assessment outcomes.

The partnership established shared responsibility for quality issues that reflected a QbD mindset and adhered to ICH E6(R3)’s sharpened focus on sponsor oversight of delegated tasks.^4,6 This focus ensures that sponsors remain accountable even when outsourcing trial activities, and it emphasizes robust governance, clear contractual agreements, and ongoing oversight of third-party vendors.

Methods: Application of Quality by Design and Risk-Based Operations

The operational framework was designed to integrate QbD and risk-based principles, aligning with both ICH E6(R2) and the advanced concepts introduced in ICH E6(R3), as well as FDA guidance on clinical trial oversight.

• QbD Framework: QbD was applied as described in ICH E6(R2) and further elaborated by ICH E6(R3) and ICH Q8(R2) principles.^1,7 This framework emphasizes building quality into the scientific and operational design and conduct of clinical trials from the outset, rather than relying solely on retrospective quality checks.⁴ Key aspects included:
  • Prospective identification of critical-to-quality (CtQ) factors: This involved early and systematic identification of factors crucial to ensuring participant safety and the reliability of primary data endpoints. Examples include key eligibility criteria, essential data elements, and crucial processes that directly affect trial outcomes.
  • Early assessment of protocol complexity and site burden: A thorough evaluation of the protocol’s design and the demands it would place on investigative sites was conducted. This proactive assessment allowed the study teams to anticipate potential risks and develop mitigation strategies.
  • Design of operational controls proportionate to identified risks: Control measures were implemented based on the level of risk associated with specific trial activities. This ensured that resources were allocated efficiently, focusing on areas with the highest potential impact on data quality and participant safety, thereby avoiding excessive procedural burden.

By embedding quality intentionally into trial execution, the QbD framework fostered a proactive approach to clinical trial management, consistent with the latest regulatory thinking.

• Risk-Based Monitoring (RBM) Strategy: The RBM strategy was developed in accordance with FDA, ICH, and EMA guidance on RBM. The strategy particularly reflected the principles outlined in ICH E6(R2) and the more nuanced approach advocated by ICH E6(R3).^1,2,4 This involved moving away from a one-size-fits-all monitoring approach to one that is proportionate to identified risks. Key elements included:
  • Monitoring plans tailored per protocol: Each study’s monitoring plan was customized based on its unique design, complexity, and identified risks, rather than being based on a generic template.
  • Monitoring intensity based on assessed risk: The frequency and nature of monitoring activities were determined by the level of risk associated with specific data points, processes, and sites, moving away from uniform, schedule-driven site visits. This included using centralized monitoring as a key component to identify trends, outliers, and potential systemic issues across sites.^2,6
  • Integration of on‑site and centralized monitoring activities: A hybrid approach was adopted, combining targeted on-site visits with robust centralized monitoring. This allowed for efficient oversight, early detection of issues, and effective resource use.
  • Empowerment of clinical research associates (CRAs): CRAs were trained and empowered to escalate issues based on their impact on CtQ factors, rather than solely on procedural deviations. This fostered critical thinking and a focus on important risks to participant safety and data integrity.

This comprehensive RBM approach improved monitoring efficiency while maintaining regulatory compliance and ensuring the integrity of trial data.

• Site Management Approach: Effective site management is crucial to the successful conduct of clinical trials. The approach followed best practices and aligned with regulatory expectations for site oversight. Key components included:
  • Site capability and experience assessments: Thorough evaluations were conducted to ensure that selected sites possessed the necessary infrastructure, resources, and experienced personnel to conduct the trial effectively and ethically.
  • Early engagement and expectation setting: Proactive communication with investigative sites from the outset established clear expectations regarding protocol adherence, data quality, regulatory compliance, and reporting requirements.
  • Continuous performance monitoring: Sites were continuously monitored for performance metrics, patient recruitment, data entry timeliness, and adherence to GCP. This allowed for early identification of potential issues and timely intervention.
  • Proactive problem resolution: A system for promptly addressing and resolving site-specific challenges was in place, preventing minor issues from escalating into major problems that could affect trial timelines or data quality.

Both academic and community sites were supported using standardized frameworks, with built-in flexibility to adapt processes to site‑specific needs while maintaining overall quality and compliance. This adaptability is crucial for successful site engagement and performance.

Results

Operational outcomes were evident across all supported studies, demonstrating the effectiveness of the QbD-driven, risk-based operational framework. The following outcomes were observed:

• Improved consistency in site performance: Standardized processes and continuous monitoring led to more uniform and higher-quality performance across all participating sites.
• Timely identification and mitigation of operational risks: The proactive risk-based approach allowed for early detection of potential issues, enabling swift implementation of mitigation strategies and minimizing their impact.
• Maintenance of inspection‑ready documentation: Rigorous adherence to QbD principles and regulatory guidelines ensured that all trial documentation was complete, accurate, and readily available for regulatory inspections.
• Reduced recurrence of common site‑level issues: By addressing root causes of problems and implementing corrective and preventive actions, the study teams reduced the frequency of recurring site-specific issues.

The sponsor also benefited from:

• Reduced internal workload related to site oversight: The CRO partnership effectively offloaded substantial operational burdens, allowing the sponsor’s internal teams to focus on strategic initiatives.
• Increased confidence in study execution across indications: The consistent application of robust quality and risk management principles instilled greater confidence in the overall conduct and outcomes of its diverse clinical portfolio.
• Ability to scale clinical development without proportional infrastructure growth: The flexible and scalable CRO model enabled the sponsor to expand its clinical development activities without a corresponding, costly expansion of its internal operational infrastructure.

Discussion

This case illustrates how a flexible CRO partnership model can operationalize QbD and risk-based principles, particularly in evolving regulatory landscapes such as ICH E6(R3) and contemporary FDA guidance. Unlike traditional transactional outsourcing, the described approach embedded CRO staff into sponsor study teams, enabling continuity and cumulative learning across studies.

This collaborative model fosters a shared commitment to quality and efficiency, which is a cornerstone of modern GCP.

Alignment with ICH E6(R2), the principles of ICH E6(R3), and FDA guidance supported regulatory confidence while allowing operational adaptability. This balance is essential for emerging biopharma organizations managing rapid growth and diverse portfolios.

The QbD and RBM strategies directly addressed the paradigm shift that ICH E6(R3) emphasized, which moved toward building quality from the start and proportionate oversight.⁴ The governance and communication frameworks established within the partnership also supported the focus of E6(R3) on enhanced data integrity and sponsor oversight of delegated tasks.⁴

Although this paper reflects a practice‑based, retrospective analysis and does not include quantitative benchmarking data, its qualitative outcomes provide valuable insights. Outcomes may vary based on sponsor maturity, therapeutic area, and internal governance structures.

The implications for practice for emerging biotechnology companies and CROs include the following:

• Early application of QbD reduces downstream remediation: Proactive quality planning minimizes costly and time-consuming issues later in the trial lifecycle.
• RBM improves efficiency and focus: By concentrating resources on key risks, RBM optimizes monitoring activities and enhances overall trial quality.
• Scalable partnerships outperform fixed outsourcing models in multistudy portfolios: Flexible CRO engagements provide the agility needed to manage diverse and expanding clinical pipelines effectively.

Conclusion

A CRO partnership model grounded in QbD and aligned with ICH E6(R2), E6(R3), and FDA guidance can effectively support complex, multiple‑indication clinical programs. By embedding quality into study design and execution, and by adopting a proportionate, risk-based approach to oversight, sponsors and CROs can achieve scalable growth while maintaining regulatory compliance, ensuring participant protection, and upholding data integrity.

This approach not only meets current regulatory expectations but also prepares organizations for future advancements in clinical trial conduct.

About the Authors

Janel Shelton-DeMagnus serves as senior director of clinical operations at Navitas Life Sciences, bringing multiple years of experience in clinical research and clinical practice as a physician assistant. Her expertise spans clinical operations, quality by design, risk-based trial oversight, and strategic study delivery, helping sponsors navigate increasingly complex clinical development programs while maintaining a strong focus on patient safety and data quality.

Ndimuangu Nchotou Hilton is a senior clinical research associate with extensive experience in clinical research, including the monitoring and management of clinical trials across multiple therapeutic areas. Throughout his career, Hilton has contributed to Phase I–IV studies, with a strong focus on ensuring data integrity, safeguarding patient safety, and supporting the conduct of research in compliance.

Sowmya Kaur, executive vice president at Navitas Life Sciences, has worked across multiple aspects of the industry, including operations, business development, and strategy with leading industry players. With a career spanning 2 decades, she has a track record of building and leading clinical development engagements across emerging markets and delivering a portfolio of projects.

References

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). 2016. https://database.ich.org/sites/default/files/ICH_E6_R2_Addendum.pdf
2. US Food and Drug Administration. Oversight of Clinical Investigations—A Risk-Based Approach to Monitoring. August 2013. Updated November 6, 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oversight-clinical-investigations-risk-based-approach-monitoring
3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R3). 2025. https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
4. Association of Clinical Research Professionals. FDA publishes ICH E6(R3): what it means for US clinical trials. September 16, 2025. https://acrpnet.org/2025/09/16/fda-publishes-ich-e6r3-what-it-means-for-u-s-clinical-trials
5. European Medicines Agency. Reflection paper on risk-based quality management in clinical trials. 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-based-quality-management-clinical-trials_en.pdf
6. European Medicines Agency. Guideline on computerised systems and electronic data in clinical trials. 2023. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-and-electronic-data-clinical-trials_en.pdf
7. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8(R2). 2009. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf